Solid IO

Organo-ID

The company develops 3D organoid models and drug response tests for cancer patients and pharmaceutical researchers to improve personalised medicine and treatment efficacy.

Oncosyne

This company develops patient-derived tumoroid drug screening platforms for pharmaceutical firms and oncologists to improve drug discovery and personalised cancer treatment.

Kiyatec

This company develops 3D cell culture platforms to predict patient-specific responses to cancer therapies for oncologists and biopharmaceutical companies.

Orakl Oncology

This company develops a predictive platform using patient tumor avatars and data to help pharmaceutical firms accelerate and de-risk cancer drug development.

Known Medicine

This company develops a platform using 3D cell culture and artificial intelligence to predict drug responses for oncologists and biopharmaceutical developers.

Pear Bio

The company develops a precision medicine platform using microfluidic chips and computer vision to predict cancer treatment efficacy for oncologists and pharmaceutical researchers.

LiquidCell Dx

This company develops blood-based liquid biopsy tests for tumor microenvironment profiling to help pharmaceutical companies and clinical partners predict cancer therapy responses.

PreComb

This company develops a precision oncology platform using patient-derived microtumour models and automated analysis to predict drug responses for biopharmaceutical firms and clinical institutions.